Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Lymphoid 2 Myeloid 1 Genitourinary 1

Conditions

Hormone Refractory Prostate Cancer 1

Interventions

pembrolizumab 164 Prednisone 130 enzalutamide 127 Docetaxel 122 Abiraterone Acetate 95 Nivolumab 93 Gemcitabine 71 Sunitinib 67 atezolizumab 50 abiraterone 50 Leuprolide 49 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48 Cisplatin 48 radium Ra 223 dichloride 39 Sorafenib 39 darolutamide 38 apalutamide 38 Ipilimumab 38 Carboplatin 37 Prednisolone 33 Everolimus 33 Axitinib 32 cabozantinib 31 avelumab 31 pazopanib 30 Bevacizumab 30 Paclitaxel 29 enfortumab vedotin 28 bicalutamide 28 Cyclophosphamide 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × bafetinib × Genitourinary × Clear all

NCT01215799 2011-12-15

PROACT

CytRx

Phase 2 Completed

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡